ADICON Holdings has terminated its agreement to buy Crown Bioscience International from JSR Life Sciences, the Hong Kong-listed company said on 16 November 2026, after the regulatory approvals needed for the US$204m deal were not obtained in time.
Deal terms and financing
Under the November 2025 agreement, ADICON's subsidiary Miramar Lifesciences was to pay about US$120m upfront plus earn-outs of up to US$84m linked to 2025 and 2027 performance targets.
Regulatory approvals and timing
The deal required regulatory approvals by an outside date that had been extended to 13 November 2026. With approvals outstanding, the buyer and seller agreed after trading hours that day to terminate the agreement with immediate effect, and no shareholder circular will be issued.
Market context
JSR, now owned by Japan Investment Corporation, agreed to sell Crown Bioscience, a San Diego-based oncology-focused contract research organisation, as part of a restructuring of its life sciences business. ADICON is backed by Carlyle.





